Author of

• 11745

  +

  P2.11 - Poster Session 2 - NSCLC Novel Therapies (ID 209)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11761

    +

    P2.11-016 - A Comparative Analysis of EGFR Mutation Status in Association with the Efficacy of TKI in Combination with WBRT/SRS/Surgery plus chemotherapy in Brain Metastasis from Non-small Cell Lung Cancer (ID 1579)

    09:30 - 09:30  |  Author(s): L. Cai
    • Abstract

    Background
    The outcomes of brain metastasis (BM) from non-small cell lung cancer (NSCLC) remain poor even with optimized option of stereotacic radiosurgery (SRS), whole brain radiotherapy (WBRT), surgery, chemotherapy or a combination. We purposed to identify the efficacy of tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) using with conventional therapy on BM patients from NSCLC and clarify the association between treatment outcome and EGFR gene mutation status.

    Methods
    Totally 282 cases treated basically with conventional therapy alone or in addition to TKI were enrolled in our study from 2003-2012. Among these patients, 178 cases were treated with conventional therapy (Non-TKI group) and 104 cases were treated with TKI plus conventional therapy (TKI group). EGFR mutation analysis was performed in 107 patients with tissue samples.

    Results
    With a median follow-up of 28 months (range, 22-34 months), the median overall survival (MOS), median progression-free survival of intracranial disease (MPFSI), and median progression-free survival for extracranial disease (MPFSE) in TKI group was 31.9, 19.8, and 19.6 months compared with 17.0 (P<0.0001), 12.0 (P<0.0001), and 12.3 (P<0.0001) months in Non-TKI group, respectively. Within TKI group, patients harboring EGFR mutation had longer time of 20.4 months to extracranial disease progression than 14.1 months in EGFR negative patients (P=0.032). In additional, EGFR positive patients had nonsignificant but potential improvements of 37 and 22.7 months for MOS and MPFSI compared with 23.4 and 16.9 months in EGFR negative patients (P=0.094, P=0.382 respectively).

    Conclusion
    Administration of TKI agents with conventional therapy might be benefit for patients with BMs from NSCLC on MOS, MPFSI and MPFSE compared with conventional therapy. Patients harboring EGFR mutation not only had significant improvement for PFSE with TKI plus conventional treatment compared with EGFR negative patients, but also non-significantly better outcome of OS and PFSI as well.